ARIDIS PHARMACEU(ARDS)
Search documents
ARIDIS PHARMACEU(ARDS) - 2023 Q3 - Quarterly Report
2023-11-06 21:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Delaware 47-2641188 (State or other jurisdiction of incorporation or organization) 983 University Avenue, Bldg. B Los Gatos, California 95032 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...
ARIDIS PHARMACEU(ARDS) - 2023 Q2 - Quarterly Report
2023-09-14 01:47
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2641188 (State or other jurisdiction of incorporation or org ...
ARIDIS PHARMACEU(ARDS) - 2023 Q1 - Quarterly Report
2023-06-08 21:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2641188 (State or other jurisdiction of incorporation or or ...
ARIDIS PHARMACEU(ARDS) - 2022 Q4 - Annual Report
2023-05-22 21:22
Washington, D.C. 20549 FORM 10-K (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38630 Aridis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-2641188 (State or other jurisdi ...